Osiris
Therapeutics OSIR today announced the conclusion of
its collaboration with Genzyme, a Sanofi company. As the Collaboration
Agreement is now ended, all rights to Prochymal® and ChondrogenTM
worldwide revert back to Osiris. Osiris is now free to commercialize or
enter into commercialization agreements for Prochymal and Chondrogen
with other parties without limitation. Both parties have agreed to an
orderly conclusion of the collaboration, with no further financial
responsibilities for either party, and an amicable end to their
relationship.
Prochymal (remestemcel-L) is a first-in-class mesenchymal stem cell
therapy indicated for the treatment of acute graft-vs-host disease
(GvHD) in children. In May, Prochymal became the world's first stem
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in